Inotiv (STU:BS50) Stock Based Compensation: €4.6 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Inotiv Stock Based Compensation?

Inotiv STU:BS50 Stock Based Compensation is €4.6 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Inotiv's Stock Based Compensation for the three months ended in Mar. 2026 was €1.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was €4.6 Mil.

Inotiv Stock Based Compensation Related Terms

Inotiv Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Inotiv's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inotiv Stock Based Compensation Chart

Inotiv Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.52 24.44 7.35 6.07 5.14

Inotiv Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.33 1.25 1.18 1.18 1.04

Inotiv Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.6 Mil.

What does a Stock Based Compensation of €4.6 Mil mean?
Inotiv (STU:BS50) has a Stock Based Compensation of €4.6 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Inotiv and its competitors.
Is Inotiv's Stock Based Compensation too high?
Inotiv's current Stock Based Compensation is €4.6 Mil.
How does Inotiv's Stock Based Compensation compare to NSTM and PRPH?
Inotiv's Stock Based Compensation of €4.6 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Inotiv and its competitors. Inotiv's current Stock Based Compensation is €4.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inotiv stock overvalued right now?
Based on GuruFocus' analysis, Inotiv (STU:BS50) is currently considered Possible Value Trap. The stock's GF Value™ is €1.43, compared to a current price of €0.04 — trading 97.2% below its estimated fair value. The current Stock Based Compensation is €4.6 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Inotiv (STU:BS50), the current Stock Based Compensation is €4.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inotiv Business Description

Other Exchanges NOTVQ:USA
Address 2701 Kent Avenue, West Lafayette, IN, USA, 47906
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.